Melanomas that develop within the eye are treated by a variety of different methods that, in general, successfully control primary tumor growth. However, all of these treatments fail to alter the incidence of metastatic disease, which is unusually high and occurs in approximately 50% of patients with medium to large tumors. Although there is a long delay between the appearance of primary tumors and the development of secondary tumors, once metastatic tumors are clinically detectable, they grow rapidly, are resistant to conventional forms of therapy, and are universally fatal. There is currently no successful treatment available for patients with metastatic melanomas derived from ocular tumors. Previous studies indicate that ocular melanomas are immunogenic tumors that express tumor antigens recognized by specific T cells. Tumor-specific lymphocytes are present within the patient s peripheral blood and among tumor-infiltrating-lymphocytes. In order to successfully activate specific T cells, the PI proposes to use a form of gene therapy that increases the immunogenicity of primary ocular melanoma cells. The ultimate goal of this research is to develop a tumor cell vaccine that protects ocular melanoma patients from developing metastatic tumors. Protection is achieved by using primary tumor cells to stimulate tumor-specific T cells that eliminate metastatic tumor cells. He hypothesizes that primary tumor cells genetically engineered to express the costimulatory molecules B7.1 and interleukin-12 will stimulate tumor-specific cytotoxic T cells among the patient's peripheral blood lymphocytes. These lymphocytes will possess the ability to eliminate metastatic tumor cells. The first specific aim will determine if primary tumor cells that express costimulatory signals (B7.1 and/or interleukin-12) induce proliferation of autologous T cells. The second specific aim will determine if tumor-specific cytotoxic T cells are present among these proliferating cells, and the third specific aim will determine if these cytotoxic T cells lyse metastatic tumor cells.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY009294-09
Application #
6342611
Study Section
Visual Sciences A Study Section (VISA)
Program Officer
Hecht, Toby T
Project Start
1993-05-01
Project End
2002-12-31
Budget Start
2001-01-01
Budget End
2002-12-31
Support Year
9
Fiscal Year
2001
Total Cost
$302,716
Indirect Cost
Name
Schepens Eye Research Institute
Department
Type
DUNS #
073826000
City
Boston
State
MA
Country
United States
Zip Code
02114
Theodoropoulou, Sofia; Kolovou, Paraskevi E; Morizane, Yuki et al. (2010) Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase. FASEB J 24:2620-30
van Ginkel, Paul R; Gee, Ricardo L; Shearer, Rebecca L et al. (2004) Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res 64:128-34
Walker, Teresa M; Van Ginkel, Paul R; Gee, Ricardo L et al. (2002) Expression of angiogenic factors Cyr61 and tissue factor in uveal melanoma. Arch Ophthalmol 120:1719-25
Ohashi, Y (1999) Introduction: all for saving the visual axis. Chem Immunol 73:1-10
Ksander, B R; Geer, D C; Chen, P W et al. (1998) Uveal melanomas contain antigenically specific and non-specific infiltrating lymphocytes. Curr Eye Res 17:165-73
Chen, P W; Murray, T G; Uno, T et al. (1997) Expression of MAGE genes in ocular melanoma during progression from primary to metastatic disease. Clin Exp Metastasis 15:509-18
Chen, P W; Murray, T G; Salgaller, M L et al. (1997) Expression of MAGE genes in ocular melanoma cell lines. J Immunother 20:265-75
Uno, T; Chen, P W; Murray, T G et al. (1997) Gene transfer of the CD80 costimulatory molecule into ocular melanoma cells using a novel episomal vector. Invest Ophthalmol Vis Sci 38:2531-9